Press Releases

Year

January 23, 2025

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

October 16, 2024

Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes

July 23, 2024

Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial

May 21, 2024

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection

April 30, 2024

Vedanta Biosciences Awarded $3.9 Million from CARB-X to Ready VE707 for First-in-Human Study for Prevention of Multidrug-Resistant Infections

April 29, 2024

Vedanta Biosciences to Present at Upcoming Investor Conferences

March 6, 2024

Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference

November 28, 2023

Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings

November 13, 2023

Topline Data of Investigator-Sponsored Study of VE303 to Treat Hepatic Encephalopathy (HE) Presented at The Liver Meeting 2023

October 30, 2023

Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium

Pages: 123